UBS AM’s Denali Therapeutics DNLI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $85.1M | Sell |
4,432,314
-551,412
| -11% | -$11M | 0.02% | 539 |
|
|
2025
Q4 | $82.3M | Sell |
4,983,726
-481,311
| -9% | -$8.12M | 0.02% | 526 |
|
|
2025
Q3 | $79.4M | Sell |
5,465,037
-797,240
| -13% | -$11.5M | 0.02% | 521 |
|
|
2025
Q2 | $87.6M | Sell |
6,262,277
-504,639
| -7% | -$7.1M | 0.02% | 564 |
|
|
2025
Q1 | $92M | Buy |
6,766,916
+3,184,042
| +89% | +$61M | 0.02% | 564 |
|
|
2024
Q4 | $73M | Sell |
3,582,874
-166,612
| -4% | -$4.27M | 0.02% | 584 |
|
|
2024
Q3 | $109M | Buy |
3,749,486
+1,451,770
| +63% | +$36M | 0.03% | 495 |
|
|
2024
Q2 | $53.4M | Buy |
2,297,716
+1,610,477
| +234% | +$30.9M | 0.02% | 604 |
|
|
2024
Q1 | $14.1M | Sell |
687,239
-21,100
| -3% | -$397K | 0.01% | 898 |
|
|
2023
Q4 | $15.2M | Buy |
708,339
+65,039
| +10% | +$1.29M | 0.01% | 850 |
|
|
2023
Q3 | $13.3M | Buy |
643,300
+76,159
| +13% | +$1.93M | 0.01% | 860 |
|
|
2023
Q2 | $13.1M | Hold |
567,141
| – | – | 0.01% | 873 |
|
|
2023
Q1 | $13.1M | Buy |
567,141
+23,218
| +4% | +$639K | 0.01% | 873 |
|
|
2022
Q4 | $15.1M | Buy |
543,923
+13,719
| +3% | +$408K | 0.01% | 820 |
|
|
2022
Q3 | $16.3M | Buy |
530,204
+42,799
| +9% | +$1.39M | 0.01% | 815 |
|
|
2022
Q2 | $14.3M | Buy |
487,405
+52,578
| +12% | +$1.38M | 0.01% | 833 |
|
|
2022
Q1 | $14M | Sell |
434,827
-5,209
| -1% | -$179K | 0.01% | 945 |
|
|
2021
Q4 | $19.6M | Buy |
440,036
+5,302
| +1% | +$251K | 0.01% | 902 |
|
|
2021
Q3 | $21.9M | Buy |
434,734
+4,863
| +1% | +$274K | 0.01% | 840 |
|
|
2021
Q2 | $33.7M | Buy |
429,871
+131,587
| +44% | +$8.14M | 0.01% | 742 |
|
|
2021
Q1 | $17M | Sell |
298,284
-111,399
| -27% | -$7.46M | 0.01% | 902 |
|
|
2020
Q4 | $34.3M | Sell |
409,683
-85,224
| -17% | -$5.15M | 0.02% | 705 |
|
|
2020
Q3 | $17.7M | Buy |
494,907
+2,238
| +0.5% | +$67.4K | 0.01% | 806 |
|
|
2020
Q2 | $11.9M | Buy |
492,669
+426,528
| +645% | +$10M | 0.01% | 860 |
|
|
2020
Q1 | $1.16M | Buy |
66,141
+8,286
| +14% | +$173K | ﹤0.01% | 1638 |
|
|
2019
Q4 | $1.01M | Sell |
57,855
-2,017
| -3% | -$33.6K | ﹤0.01% | 1912 |
|
|
2019
Q3 | $917K | Buy |
59,872
+10,461
| +21% | +$200K | ﹤0.01% | 1998 |
|
|
2019
Q2 | $1.03M | Buy |
49,411
+19,666
| +66% | +$441K | ﹤0.01% | 1871 |
|
|
2019
Q1 | $691K | Buy |
29,745
+9,972
| +50% | +$209K | ﹤0.01% | 1971 |
|
|
2018
Q4 | $409K | Buy |
19,773
+5,073
| +35% | +$92K | ﹤0.01% | 2079 |
|
|
2018
Q3 | $320K | Buy |
+14,700
| New | +$243K | ﹤0.01% | 2256 |
|
Other funds holding DNLI
VCM
VPM
BBA
UBS AM's DNLI Position: Q1 2026 in Review
UBS AM reduced its Denali Therapeutics (DNLI) stake by 11% in Q1 2026, selling an estimated $11M and leaving 4,432,314 shares worth $85.1M. The position accounts for 0.02% of the portfolio, ranked #539.
UBS AM first reported a position in DNLI in Q3 2018 and has held it in 31 quarters since. The position peaked at $109M in Q3 2024. 268 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.
- UBS AM held 4,432,314 shares of Denali Therapeutics worth $85.1M as of Q1 2026.
- UBS AM sold 551,412 Denali Therapeutics shares in Q1 2026, an estimated $11M.
- Denali Therapeutics made up 0.02% of UBS AM's portfolio in Q1 2026, its #539 holding.
- UBS AM first reported a position in Denali Therapeutics in Q3 2018 and has held it in 31 quarters since.
- UBS AM's Denali Therapeutics position peaked at $109M in Q3 2024.
- 268 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.
Based on UBS AM's 13F filing for Q1 2026, filed 13 May 2026.